With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

The collaboration, set to begin on 1 July, will see Novo Nordisk team up with the telehealth company to offer Wegovy to ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

European stocks rose sharply Friday after U.S. Commerce Secretary Howard Lutnick said the U.S. and China had agreed to restore their trade truce and that more deals were imminent. Also lifting the ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

No matter how much you love these speculative winners, you don’t have a gain until you actually ring the register.

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Uninsured or self-pay obesity patients can get any dose of Wegovy for $299 from July 1–31, 2025. Patients can get their ...

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...

Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, ...

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS) securities ...

Novo Nordisk plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.